1. Clinical Overview

Molecule: Heptapeptide Met-Glu-His-Phe-Pro-Gly-Pro, synthetic analog of ACTH(4–10) without hormonal activity

Classification: Nootropic • Neuroprotective/neuroplasticity • Anti-fatigue/anti-stress • ADHD adjunct • Post-stroke neurorehabilitation • Dopaminergic–glutamatergic modulator

One of the most widely used therapeutic nootropics in Russian clinical practice, approved for stroke recovery, cognitive decline, TBI, ADHD, and asthenic CNS disorders.

2. Mechanisms of Action

2.1 BDNF Upregulation (Primary)

Significantly increases BDNF and neurotrophins: enhanced synaptic plasticity, faster learning/memory, improved mood/resilience, neurogenesis. One of the strongest pro-neuroplastic peptides.

2.2 Dopamine & Prefrontal Enhancement

Increases dopamine in PFC and hippocampus: focus, working memory, executive function, ADHD reduction. Does NOT deplete dopamine stores.

2.3 Glutamate Receptor Modulation

AMPA & NMDA modulation: learning speed, memory encoding, mental stamina, neuroplasticity during rehab.

2.4 Anti-Inflammatory & Neuroprotective

Reduces cytokines, oxidative stress, excitotoxicity, neuronal apoptosis. Stroke, TBI, neurodegeneration.

2.5 Cerebral Blood Flow

Improves microcirculation, oxygen utilization, brain metabolic efficiency.

3. Clinical Applications

3.1 ADHD

Focus, executive functioning, reduced distractibility, calmer cognition. Adults, stimulant-sensitive, add-on therapy.

3.2 Cognitive Enhancement

Executives, students, researchers, high-stress professionals. Faster processing, mental stamina, memory, focus under pressure.

3.3 Stroke / Ischemic Rehab

Russian clinical trials: faster neurological recovery, motor function, speech, reduced post-stroke cognitive deficits. Pairs with Pinealon.

3.4 TBI Support

Reduces neuroinflammation, improves cognitive symptoms, enhances neuroplastic recovery. Not FDA-approved.

3.5 Fatigue & Burnout

Mental exhaustion, cognitive fog, stress-induced fatigue.

3.6 Anxiety (Non-Sedating)

Calm clarity, reduced rumination, improved resilience. Pairs with Selank.

4. Administration & Protocols

4.1 Intranasal (Preferred)

Standard/ADHD: 300–600 mcg IN 1–2×/day
High-Performance: 600–900 mcg IN 1–2×/day
Stroke/TBI: 900–1,200 mcg IN 2–3×/day × 10–14 days then taper
Acute Demand: 600–1,200 mcg 30–60 min before task

4.2 SC

300–600 mcg SC daily. Systemic, less common.

4.3 Sublingual

500–1,000 mcg SL 1–2×/day.

Cycling

Cognitive: 10–30 days. ADHD: 5 on/2 off. Recovery: 14–30 days. Not habit-forming; long-term with breaks.

5. Combination Therapy (Peptide Protocol Portal Synergy)

+ Selank: Classic synergy — cognitive stimulation (Semax) + anxiolysis (Selank). Anxiety + ADHD
+ Pinealon: Mitochondrial/neuroprotective + neuroplastic/cognitive. Aging
+ DSIP: Deep sleep restoration + daytime performance. Burnout
+ NAD+ / SS-31: Neuroenergy, mitochondrial repair, cognitive endurance
+ Tesofensine: Balances stimulant properties with neuroplastic stability
+ Oxytocin Acetate: Social cognition, emotional fluency, relationship anxiety

6. Clinical Decision Trees

Tree 1 — Is Semax Indicated?

Cognitive enhancement needed? → YES

ADHD symptoms? → YES

Stroke / TBI recovery? → YES (research)

Chronic fatigue / burnout? → YES

Anxiety with cognitive dulling? → YES (combine Selank)

Major depressive disorder? → Adjunctive only

Tree 2 — Dosing

Focus / cognition → 300–600 mcg IN daily

Executive performance → 600–900 mcg IN 1–2×/day

ADHD → 300–600 mcg IN 2–3×/day (5 on/2 off)

Post-stroke → 900–1,200 mcg IN 2–3×/day

Burnout / fatigue → 300–600 mcg IN AM

7. Integrated Archetypes

A — Cognitive Enhancement

Semax IN daily + Pinealon AM + NAD+ weekly + SS-31 energy
Outcome: Sharper cognition, better memory, enhanced processing.

B — ADHD Optimization

Semax 300–600 mcg IN 2–3×/day + Selank 250–500 mcg PRN + L-tyrosine
Outcome: Stable focus without stimulant crash.

C — Neurorehabilitation

Semax 1,000 mcg IN 2–3×/day + Pinealon + BPC-157 neurovascular + SS-31 mito
Outcome: Accelerated functional recovery.

D — Burnout / Stress Collapse

Semax AM + Selank evening + DSIP nightly + MOTS-c weekly
Outcome: Deep restoration + improved productivity.

8. Expected Timeline

10–30 min: Cognitive enhancement onset
Day 1–3: Improved focus & processing
Week 1–2: Enhanced productivity & working memory
Week 2–4: Significant ADHD improvement
Week 4–8: Neuroplastic gains & stable cognition

9. Contraindications

Absolute

Pregnancy / Breastfeeding
Active psychotic disorder

Relative

Severe anxiety with hyperarousal (use with Selank)
Bipolar disorder (monitor hypomania)
Nasal mucosal pathology

10. Adverse Effects

Very well tolerated. Possible: mild overstimulation, dry nose/nasal irritation, headache, slight mood elevation, restlessness (high doses). Rare: sleep disruption, emotional blunting (very high dosing). No dependence or withdrawal.

11. Monitoring

Cognitive performance measures
ADHD symptom tracking
Mood & anxiety tests
Sleep quality
HRV / stress markers
Work output & mental stamina

Legal Disclaimer

This document is provided solely for educational and informational purposes. Semax (MEHFPGP) and other peptides are not FDA-approved drugs. Peptide Protocol Portal makes no representations or warranties. By using this document, the reader agrees that Peptide Protocol Portal shall not be held liable. Use at your own risk.

References — Semax

Foundational Discovery

1. Ashmarin, I. P., et al. ACTH(4–7)-based peptides: Semax. Neurosci Behav Physiol, 28(6), 680–685 (1998).

2. Kamensky, A. A., et al. Structural–functional properties. Peptides, 18(2), 295–302 (1997).

3. Baĭkov, V. G., et al. Design of Semax. Bull Exp Biol Med, 130(2), 159–162 (2000).

4. Ashmarin, I. P., & Kamensky, A. A. Mechanistic overview. Neurochem J, 1(1), 22–30 (2007).

Neuroprotection & Ischemia

5. Skvortsova, V. I., et al. Acute ischemic stroke efficacy. Neurosci Behav Physiol, 30(6), 671–675 (2000).

6. Andreeva, L. A., et al. Reduces apoptosis after ischemia. Neurosci Lett, 391(1–2), 23–27 (2005).

7. Inozemtsev, A. N., et al. Ischemia/reperfusion protection. Brain Res, 1210, 39–47 (2008).

8. Kochetova, O. V., et al. Oxidative stress in cerebrovascular. Exp Biol Med, 234(7), 828–835 (2009).

9. Petrov, A. M., et al. Neurovascular recovery post-stroke. J Stroke Cerebrovasc Dis, 21(8), 663–670 (2012).

BDNF & Plasticity

10. Volodina, O. V., et al. BDNF and synaptic plasticity. Neurochem J, 7(2), 121–128 (2013).

11. Glazova, N. Y., et al. Neurotrophic/synaptic gene expression. Mol Biol Reports, 38(8), 5539–5546 (2011).

12. Andreeva, L. A., et al. Prevents stress-induced BDNF downregulation. Russ J Physiol, 95(3), 311–319 (2009).

Cognition & Memory

13. Neznamov, G. G., et al. Cognitive impairment clinical evaluation. Clin Pharmacol Ther, 6(3), 47–52 (2000).

14. Shevchenko, G. G., et al. Attention/memory under cognitive load. Human Physiol, 30(6), 653–658 (2004).

15. Dolotov, O. V., et al. Enhances associative learning. Neurosci Behav Physiol, 29(6), 731–737 (1999).

16. Gulevich, G. V., et al. ADHD-like symptoms. Russ J Psychiatry, 2, 37–45 (2011).

Anti-Inflammatory & Stress

17. Karelina, T. V., et al. Cytokine cascades/neuroinflammation. Bull Exp Biol Med, 147(4), 389–392 (2009).

18. Glazova, N. Y., et al. Antioxidant gene expression. Biochemistry (Moscow), 78(6), 701–708 (2013).

19. Vetvicka, V., & Vetvickova, J. Neuroimmune modulation. Biomed Pharmacother, 68(3), 343–349 (2014).

20. Yermakova, N. N., et al. Stress-induced behavioral/endocrine. J Neuroendocrinol, 20(8), 1034–1041 (2008).

Neurotransmitter Modulation

21. Kozlovskaya, M. M., et al. Serotonergic/dopaminergic turnover. Neurochem J, 1(4), 271–278 (2007).

22. Andreeva, L. A., et al. Noradrenergic regulation. Neurosci Lett, 429(2), 125–130 (2007).

23. Dubrovina, N. I., et al. Memory via glutamatergic pathways. Behav Brain Res, 182(1), 12–20 (2007).

Clinical Trials

24. Skvortsova, V. I., et al. Integrated stroke therapy outcomes. Zh Nevrol Psikhiatr, 101(8), 25–30 (2001).

25. Neznamov, G. G., & Teleshova, E. S. Neurasthenia efficacy. Consilium Medicum, 7(3), 45–50 (2005).

26. Medvedev, I. N., et al. Vascular cognitive impairment. Neuropsychiatr Dis Treat, 4(4), 805–812 (2008).

Genomic & Epigenetic

27. Ashapkin, V. V., et al. Short peptides modulate epigenetic gene expression. Epigenomics, 7(1), 129–139 (2015).

28. Khavinson, V. K., et al. Genome-wide regulation. Bull Exp Biol Med, 155(4), 464–468 (2013).

Safety & Toxicology

29. Seredenin, S. B., et al. Long-term safety. Exp Clin Pharmacol, 74(6), 11–15 (2011).

30. Ashmarin, I. P., et al. Safety of regulatory peptides. Cell Tissue Biol, 5(4), 299–307 (2011).

31. Golubev, A. G., et al. No addiction/tolerance/withdrawal. Exp Biol Med, 236(3), 320–328 (2011).